CytomX Therapeutics (CTMX) Stock Analysis & AI Equity Report
CytomX Therapeutics (CTMX) overview
CytomX Therapeutics (CTMX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 76.2m and operating profit of USD -22.4m; the year-end share price was 4.26 USD and market capitalisation was USD 725m. CytomX Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get CytomX Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology therapies. Its PROBODY platform uses tumor-associated proteases to conditionally activate masked biologics, including antibody-drug conjugates, T-cell engagers and cytokines. The company’s clinical programs include varsetatug masetecan, an investigational antibody-drug conjugate targeting EpCAM, and CX-801; its pipeline also includes preclinical programs.
Generate the CytomX Therapeutics report
CytomX Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for CytomX Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on CytomX Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.